US7599161095 - Common Stock
Webcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ET...
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer,...
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
RGEN stock results show that Repligen missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12%...
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life...
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of...
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET...
U.S. life sciences toolmakers Danaher (DHR), Repligen (REGN), and Bio-Rad (BIO) see gains as German peer Sartorius (SARTF) posts strong Q4 2023 results. Read more here.
A company with a $50 price per share might have a million shares outstanding or a billion shares outstanding. And unless you know, you don't know the price tag of the stock you're about to buy.
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
Repligen announces $600M convertible senior notes issuance, boosting its year-end cash and cash equivalent guidance to $717M-$727M.
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately...
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...